Pelubiprofen
Clinical data | |
---|---|
Trade names | Pelubi |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H18O3 |
Molar mass | 258.317 g·mol−1 |
3D model (JSmol) | |
| |
|
Pelubiprofen is a nonsteroidal anti-inflammatory drug of the profen class used to treat back pain and osteoarthritis.[1]
Pelubiprofen was developed in South Korea by Daewon Pharmaceuticals and it is marketed in Korea and Russia,[2] among other countries.
Research[edit]
Pelubiprofen is being studied for use in combination with eperisone.[3]
Because pelubiprofen has low water solubility, development of salt formulations with better solubility are being studied.[4]
References[edit]
- ^ "Pelubiprofen - Daewon Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.
- ^ Chan-Hyuk K (26 September 2023). "Daewon Pharm wins $3 million deal to export Pelubi to Indonesia". Korea Biomedial Review.
- ^ "(Eperisone + pelubiprofen) by Daewon Pharmaceutical for Low Back Pain: Likelihood of Approval". pharmaceutical-technology.com. 5 June 2023.
- ^ Park JY, Oh DH, Park SW, Chae BR, Kim CW, Han SH, et al. (May 2021). "Development of Pelubiprofen Tromethamine with Improved Gastrointestinal Safety and Absorption". Pharmaceutics. 13 (5): 745. doi:10.3390/pharmaceutics13050745. PMC 8158122. PMID 34070062.